Diabetes and the Eye
Diabetes mellitus is the most common cause of new blindness in working-age adults in developed countries. Elevated blood glucose damages small blood vessels throughout the body -- the eye's retinal vasculature is particularly vulnerable. Ocular manifestations of diabetes include diabetic retinopathy (DR), diabetic macular edema (DME), accelerated cataracts, and increased glaucoma risk. The CPOA frequently works with diabetic patients in both primary eye care and retina specialty settings.
Diabetic Retinopathy
Diabetic retinopathy is caused by damage to retinal capillaries from chronic hyperglycemia, leading to:
- Pericyte loss (cells that support capillary walls)
- Capillary microaneurysms (outpouchings of vessel walls)
- Vascular leakage (exudates, retinal thickening)
- Capillary closure (ischemia)
- Neovascularization (new, fragile vessels that bleed easily)
Staging of Diabetic Retinopathy
| Stage | Features | Vision Risk |
|---|---|---|
| Mild NPDR | Microaneurysms only | Low |
| Moderate NPDR | Microaneurysms, dot/blot hemorrhages, hard exudates, cotton wool spots | Moderate |
| Severe NPDR | 4-2-1 rule: hemorrhages in all 4 quadrants OR venous beading in 2+ quadrants OR IRMA in 1+ quadrant | High -- 52% risk of PDR within 1 year |
| PDR (Proliferative) | Neovascularization of disc (NVD) or elsewhere (NVE); vitreous or preretinal hemorrhage | Severe; risk of tractional retinal detachment |
NPDR = Non-Proliferative Diabetic Retinopathy; PDR = Proliferative Diabetic Retinopathy; IRMA = Intraretinal Microvascular Abnormalities.
💡 Clinical Tip: The 4-2-1 rule for severe NPDR is a key clinical benchmark. Remembering it helps prioritize which patients need more frequent monitoring or earlier laser treatment. Severe NPDR has a greater than 50% chance of progressing to PDR within one year without intervention.
Diabetic Macular Edema (DME)
DME can occur at any stage of DR and is the most common cause of vision loss in diabetic patients. It occurs when fluid leaks from damaged retinal vessels into the macular area, causing retinal thickening that distorts and blurs central vision.
Clinically significant macular edema (CSME) by ETDRS criteria involves retinal thickening within or adjacent to the center of the macula, or hard exudates near the fovea. OCT is the gold standard for detecting and monitoring DME.
Treatment
Medical / Systemic
Systemic glycemic control (HbA1c target <7%), blood pressure control, and lipid management are foundational. Studies show that tight glucose control reduces the risk of developing DR and slows progression.
Anti-VEGF Injections (First-Line for DME)
Anti-VEGF therapy has replaced laser as first-line treatment for center-involving DME. Options include bevacizumab, ranibizumab, aflibercept, and faricimab. They reduce VEGF-driven vascular leakage and improve visual acuity. Intravitreal injections are given monthly initially, then as needed.
Laser Photocoagulation
- Focal/grid laser: treats specific microaneurysms and areas of leakage in DME; still used when anti-VEGF is not feasible
- Panretinal photocoagulation (PRP): for PDR -- destroys ischemic peripheral retina to reduce the drive for neovascularization. PRP can narrow peripheral visual fields and worsen night vision but preserves central vision and prevents blindness from vitreous hemorrhage or tractional retinal detachment.
⚠️ Common Mistake: Do not assume that good visual acuity means no diabetic eye disease. Many patients with moderate to severe NPDR or early DME have 20/20 vision. Dilated fundus exams are essential regardless of acuity. Screening schedules vary by diabetes type and duration.
Screening Recommendations
| Diabetes Type | Initial Exam | Follow-up |
|---|---|---|
| Type 1 | 5 years after diagnosis | Annually if no DR; more frequent if DR present |
| Type 2 | At diagnosis | Annually if no DR; more frequent if DR present |
| Pregnancy (pre-existing DM) | First trimester | Every trimester; rapid progression can occur |
CPOA Role in Diabetic Eye Care
- Performing dilated fundus examination preparation (instilling dilating drops)
- Obtaining best-corrected visual acuity
- Acquiring OCT imaging (macular volume scans to detect DME)
- Setting up wide-field fundus photography for DR documentation
- Preparing patients for anti-VEGF injections (anesthetic drops, betadine prep)
- Educating patients on the importance of glycemic control and regular eye exams
- Noting when a patient reports sudden vision loss or floaters (vitreous hemorrhage) for urgent physician assessment
Key Takeaways
- Diabetic retinopathy progresses from NPDR to PDR; severe NPDR has >50% risk of progressing to PDR in 1 year
- DME is the most common cause of vision loss in diabetics; anti-VEGF injections are first-line
- PRP is used for PDR to reduce neovascularization
- Good visual acuity does not rule out significant diabetic eye disease -- dilation is essential
- Type 2 diabetics need a dilated exam at diagnosis; annual screening thereafter
- Systemic glucose, BP, and lipid control are foundational to preventing DR progression